<SEC-DOCUMENT>0001015820-20-000020.txt : 20200416
<SEC-HEADER>0001015820-20-000020.hdr.sgml : 20200416
<ACCEPTANCE-DATETIME>20200415214344
ACCESSION NUMBER:		0001015820-20-000020
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20200331
FILED AS OF DATE:		20200416
DATE AS OF CHANGE:		20200415

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			QIAGEN N.V.
		CENTRAL INDEX KEY:			0001015820
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38332
		FILM NUMBER:		20794952

	BUSINESS ADDRESS:	
		STREET 1:		HULSTERWEG 82
		CITY:			PL VENLO
		STATE:			P7
		ZIP:			5912
		BUSINESS PHONE:		31-77-35566-00

	MAIL ADDRESS:	
		STREET 1:		HULSTERWEG 82
		CITY:			PL VENLO
		STATE:			P7
		ZIP:			5912

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	QIAGEN NV
		DATE OF NAME CHANGE:	19960531
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a2020aprilrelease.htm
<DESCRIPTION>6-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Document</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s4365AAD4686C5B4DB1197456281FEC02"></a></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Washington, D.C. 20549</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">__________________________________</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM 6-K </font></div><div style="line-height:33%;padding-top:12px;text-align:center;padding-left:288px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">__________________________________</font></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Report of Foreign Private Issuer</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Pursuant to Rule 13a-16 or 15d-16 under</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">the Securities Exchange Act of 1934</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">For the monthly period ended March 31, 2020 </font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commission File Number 001-38332</font></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;__________________________________</font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:24pt;"><font style="font-family:inherit;font-size:24pt;font-weight:bold;">QIAGEN N.V.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Translation of registrant&#8217;s name into English)</font></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;__________________________________</font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Hulsterweg 82</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5912 PL Venlo</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">The Netherlands</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">__________________________________</font></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Form 20-F&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#253;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form 40-F&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><hr style="page-break-after:always"><div><a name="sBED8004E3FC45B4C82D408CDBD8DAE3D"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sBED8004E3FC45B4C82D408CDBD8DAE3D"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">QIAGEN N.V.</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Form 6-K</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">TABLE OF CONTENTS</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:83%;"></td><td style="width:17%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Item</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Page</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other Information</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-align:center;" href="#sF2C6EEAA1C72507DBB279AF2D2DDD4E5">3</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Signatures</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-align:center;" href="#sFC2715A5F4DF50F4BF2146AFB9BF4410">4</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exhibit Index</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-align:center;" href="#s8C73A40518705A1C9F6D131E3C399CB6">5</a></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:22px;padding-top:22px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><a name="sF2C6EEAA1C72507DBB279AF2D2DDD4E5"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sBED8004E3FC45B4C82D408CDBD8DAE3D"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OTHER INFORMATION</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April 9, 2020, QIAGEN N.V. (NYSE: QGEN; Frankfurt, Prime Standard: QIA) issued a press release announcing preliminary sales and adjusted earnings per share results for the first quarter of 2020. The press release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:22px;padding-top:22px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><a name="sFC2715A5F4DF50F4BF2146AFB9BF4410"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sBED8004E3FC45B4C82D408CDBD8DAE3D"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:50px;"></td><td style="width:182px;"></td><td style="width:449px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">QIAGEN N.V.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Roland Sackers</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Roland Sackers</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: April 15, 2020 </font></div><div style="line-height:120%;padding-bottom:22px;padding-top:22px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><a name="s8C73A40518705A1C9F6D131E3C399CB6"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sBED8004E3FC45B4C82D408CDBD8DAE3D"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT INDEX</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:16%;"></td><td style="width:6%;"></td><td style="width:78%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;text-align:center;">Exhibit</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;text-align:center;text-decoration:underline;">No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;text-decoration:underline;">Exhibit</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Press Release dated April 9, 2020</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><a name="sC1D6CB40C262519E848FF5D61DB30A53"></a></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exhibit 99.1</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div><img src="qgennewheaderlogoa52.jpg" alt="qgennewheaderlogoa52.jpg" style="height:88px;width:678px;"></div></td></tr></table></div></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">QIAGEN announces preliminary Q1 2020 results </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Venlo, The Netherlands, April 9, 2020 -</font><font style="font-family:Arial;font-size:11pt;">&#32;QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced preliminary sales and adjusted earnings per share results for the first quarter of 2020. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Net sales rose approximately 9% at constant exchange rates (CER) compared to the outlook for the first quarter announced on February 4, 2020, for approximately 2-3% CER growth. Sales results reflected very significant demand for solutions used in COVID-19 pandemic testing against weaker customer demand trends in other product areas. Adjusted earnings per share (EPS) are expected to be about $0.34-0.35 CER based on preliminary results compared to the outlook for the first quarter for approximately $0.28-0.29 CER.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Based on actual exchange rates as of March 31, 2020, QIAGEN expects currency movements against the U.S. dollar (reporting currency) to have an adverse impact on results for the first quarter of 2020 of about two percentage points on net sales at actual rates, and resulting in an adverse impact of up to $0.01 per share on adjusted EPS.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Further information will be provided when QIAGEN reports full results for the first quarter of 2020 in early May 2020.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">About QIAGEN</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&amp;D and industrial applications, primarily forensics). As of December 31, 2019, QIAGEN employed approximately&#160;5,100&#160;people in over 35 locations worldwide. Further information can be found at</font><font style="font-family:inherit;font-size:11pt;color:#505050;">&#160;</font><font style="font-family:Arial;font-size:11pt;color:#0000ff;text-decoration:underline;">http://www.qiagen.com</font><font style="font-family:inherit;font-size:11pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Forward Looking Statement</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-style:italic;">Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, launches, regulatory submissions, collaborations, markets, strategy, taxes or operating results, including without limitation its expected net sales, net sales of particular products (including anticipated sales of its QuantiFERON latent TB Test, its portfolio of next generation sequencing solutions and QIAstat-Dx), adjusted net sales, adjusted diluted earnings per share results, product launches (including anticipated launches of digital PCR products, a new version of its QuantiFERON-TB test, QuantiFERON-TB Access, the QIAstat-Dx panel for respiratory conditions and a CE-IVD marked panel for meningitis), placements of QIAsymphony modular PCR instruments, improvements in operating and financial </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div><a name="sA4709454D7755D8786A5831B2F5A3BD7"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-style:italic;">leverage, currency movements against the U.S. dollar, and plans for investment in its portfolio and share repurchase commitments, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics); variability of operating results and allocations between customer classes; the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses; as well as the possibility that expected benefits related to recent or pending acquisitions, including the pending acquisition by Thermo Fisher Scientific Inc., may not materialize as expected; and the other factors discussed under the heading &#8220;Risk Factors&#8221; contained in Item 3 of our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">QIAGEN</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.61013645224172%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:28%;"></td><td style="width:22%;"></td><td style="width:29%;"></td><td style="width:21%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Investor Relations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Public Relations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">John Gilardi</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">+49 2103 29 11711</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Thomas Theuringer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">+49 2103 29 11826</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Phoebe Loh</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">+49 2103 29 11457</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Robert Reitze</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">+49 2103 29 11676</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">e-mail: </font><font style="font-family:Arial;font-size:11pt;color:#0000ff;text-decoration:underline;">ir@QIAGEN.com</font><font style="font-family:Arial;font-size:11pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">e-mail: </font><font style="font-family:Arial;font-size:11pt;color:#0000ff;text-decoration:underline;">pr@QIAGEN.com</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:12px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>qgennewheaderlogoa52.jpg
<TEXT>
begin 644 qgennewheaderlogoa52.jpg
M_]C_X  02D9)1@ ! 0$       #_[@ .061O8F4 9      !_^$ %D5X:68
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M P,# P,#_\  $0@ : ,@ P$1  (1 0,1 ?_$ !T  0 " @(#
M   ("08' 0H#! 7_Q  Z$  ! P,"!0,# P(#" ,      P0% 08' @@3UA>7
M6!$4"2$C%1(S%C%!(D,D4<%38Y,TA HF&$C_Q  = 0$  P # 0$!
M    !08' P0( @$)_\0 5!$!  $" @4) P4*"0D)      ,$!0$"$1,4!@<A
M$B.CTU25%U<Q,PA!42*#%6&!D3)#4V-S)!;P<:'!0I,T1 FQX6*"DK*S9#71
M\5)RPH24577_V@ , P$  A$#$0 _ ._P
M
M
M
M
M
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M#ER\R?YOG;$(9,
M
M&J<JVNK<$8V>-ED$G$-I=JUHZ51;H:VCC0E5S^IPXUZ4$:IZFVC5ZZ_\)8-W
M;K%;:O')488ZB7###'Y?9_WJ_O#;)*ZEPDB_&CY6IL6VRG.2>B:1DX1]%QFM
MPBKJAYN-F=>MYK352JUJK%.WB"%4*5^Y13ZU_L6?>6[[)1['JY]IE_.Q:O\
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MO3=&FT-4G;GYG53B:6'\DATY!1M_7W7XKW?YS@?^,3OVU2[!]HZN;9OU4O\
MQ/=]8B?LFJVW[/TP[1^MCT_@]XSO)-ETB(^/F:2D<A&Q<4PBI!S+R#"(2T:V
MB=4DG7N)-9%EZ+>G[55*?4@K!?-?GEI<8\<:F:?6]%AC)CR_)HT?)\^A+7NR
M2Q11RPR?L\,&K9-AZV%&>E2Y57;)PG(,O:L/QS]I(M];;4HBLLK5PQ5<,ZUU
M*(Z/3AZZT^A'[SW>"KQRT$&&/-BQ^7#'#'YO9CAAC\ORN[NS;9J;#&LET:9<
M&]BHK<
M                                                    5@?)U/7;
M&6-CF)BUGC>T9V=F]-U:FRJB*#N0CVD<XMN+?U2_Q.&R]%'KFB6K_!^MG12O
M[9MO!*DM]1=:V>?##[1BAR8P_P 6.;-A)C_N9?\ 791Q6J:V*WTL%-_99),^
M$O\ LX:O_P!: ^RNX;UAMP%IM[*HX<+3;><8S45H453CY.,2AY)_2LGZ_8]N
MQ712<I*T_P Y$U3B90VJIW2J)[GARPZK58_-CC)CAR?AQP^_]UG6XE370;QQ
MX6[V3:W6_>BT_P"5&ZYIFXI^X9J9NM\_?7+)22Z\XZDJ*)R&N0HK]WW7%I3@
M.$%_M<+_ "?VRXT%+24=+'147_3(?=*M65-5454M96?VE*W<%?.5I[!^V=E>
M;J8K"2%J7 _37>:G5/Y#(QES2$/#OYCB_1\_8V<BQ5355XWVGE7'$_U"A1MT
MK38:/>F]SVW4[5#/%]7T6LDU7S=)K.3]'S/R>E<MY*Z\S[NVF*L_L^,,OUFB
M71_P]7_6/4V=WAD^W+DR0VQWJDG5->(<A3#N+:T6=(4E8B#4<VO*(L*4717E
MD)RK9)M7]U6BWMZ_12I]<1K?8*NEH<UX]N%SI8M/W))>E^KU?\WMT.'<>KO,
M%3786[Y*.7^2+H_K-8B=JDY)21U3&J0?J2VIY^2U2VMPY_*>_P"+[JC[W_&X
M_P"0X].+Q30,((L(M1A%^S*?KI=;KO[TEWO!O+)]R.,+-;_<2*;?5ABPYY%F
MY349Z'D[,L%M5QSKMK3['YA99+A.OV>#1']M,SWAS;+#117*:S__ &DL7U<?
MNX_U:Z;[W"Z5&PPW/N44OUGY3ZQ(+XP9R[JWCD2W=*CQ:QJ6RTEW:>O6HHPC
M[LK)M6L91I2OV$'$K$^^XW"^JM&:?$_;3*CQPHZ#"@H:W#_JF$VK^JPBTX_@
MS\S'ZQ8N$]3785U328_],PBP^]+IPT8_Z^3G_P!6N:/.C<P
M
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M_4%38I:*&@O-+AA+HAT\RHC]WCG^GIEZ/Z&&.LDDQT9X_I_(OG/-;TD
M
M                                         5'_ "[_ !XZ]^N';45M
MF[[=LC*&%7=R7!9LQ>BKIK9;Z%N-I%IWG!W'),F[UQ!(.4+=9.DG]&[BB*K.
MFC6GPE5%$]IX)\6X>%E[J<UTCFDW<KX\F6IU7-PSY-5FS8QRX<[###-J\))/
MH:S)IPS8XZ>1C'&?A%5\6K134-GDU6\E--CLW)CCK,9L,,F:#Z&G/TF.6/##
M1AFY<,.32IL^)'XNK4BMR3?*F4]R&V+*+G&#.X$XG#N"<SVQE:;?3,K#R]L+
M2E^UMY9'\)#1+.3<JI(Z*K+KN_T54X":2B2FK\6_B?W7WKW:EW6W"UTM55XQ
M:V675='''+K.CCUDGT_DQQ^[CRY\5<W(^!KC7P?O--OUQEL%TM%KZ7"EVB@K
MZ>.HSRQ\S^T5%-3QXQ\R3W<>GGXZ-/)[S0=Y? 5EZY,RWA;^W+.VWW(F(X:Z
MGC-Y<;_(=%+LQFQU/WE4H')EN0$-,K(W-%-V2K;T;5]':R/$JFW]5$V]^L/Q
M=;D5-APGN]-6_O)%[V*/5R1R2?HY-;R?6^[_ $C)=\/@GXI[OWBFU46R[N7#
M#6TLM;%54^>2#]'T.BIPZ3#Z<>.B3]'I3QW"_#+8NX+:GMVL_9UG;%U\Y$VQ
M6].V//32ET-G]GY&UWA/O,B715W,6FM>*UGSZ-U3SUU%M54UD:,WOMU%$TTT
MU3+N'GQ/TU'OG=KQO)%C+8[O4128[/C%))3XQ1811:,.CUF&,>$>LY8^6/"3
M1RM-XM_"#O19=U;+NUFI:RU;Q6^"71]I4LM'MD<LNLDDZ2+&3)HJ-9J_>1X<
ML>GDTM0?'/\ &3@_$&2,J6QNXW2;9'^7+\QUD# D#M\Q[F^S9B_(=')D O;-
MW3$PV>/8R=0O!"$>N6L>Q;-7'!XW'JI11-/13EXM_%'9;]A16G</^Z5L53++
M4ZOI)*>761QX182>[UGO-9^KU:=X4? =QFL&[E;Q WVW;O<NZ-9;98HJJ*@K
M\:/"GJ(N9)48UF--'!HU?)'C')CDY=9K4+;Q^#O(MB9O7QM=V[C:):%E-GJ"
M[F\;ORDQMR[VEMNU:K-73_$\G5I.(7.O%Z^(DVJ^I&JU^GY"FC[AIF;XPN'4
M%FUU935L.\F.&&.S=%ATF/\ S&M]W_IZOZMDME^ /CWO-5;;NS;:RX[HRSXX
M9*VFH*^HPY,=&CF1TV,>,FG#ECUG,P_.8+%M]7Q 6MN7IAY79/G3%%TWSAC
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M4DF,$L<&>FRXY9,^HFDCR99^=CFBS9]7IR9,N,7RXZ78%/.S<P
M
M                                0S<9RW2).%DF^R"ZWB":ZNA%UISQ
M@QO1=/0I^E)Q5%6XZ+(T62I_2OU(G-5W33_8<?ZV-ND'#G@W)'TW$2BBQ_\
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M6FT2XY]95YX)JC+%HCS9LFF&GRYI<^&?/AEC^AEQYO/Y^;Z.7,C/7.VZJO\
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M%-'45>:HCHXYIZW&2HFBSSY]CCSXXT\5-'S\\O1\W')ER3Q)9YO
M
M
M
M
M
M
M
4                       !_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
